NCT02276963View on ClinicalTrials.gov

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

February 15, 2019

Conditions
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Ublituximab

Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.

Trial Locations (1)

21287

Johns Hopkins University School of Medicine, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT02276963 - Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses | Biotech Hunter | Biotech Hunter